Introduction

Understanding Bispecific Antibodies

Bispecific Antibodies or CAR T-cell Therapy?

Eligibility and Administration

Treatment Administration

Step-up Dosing Explained

Transferring Care

Do I Need A Caregiver to Receive Bispecifics?

Early Access Programs

Treatment Course

Duration of Treatment

Side Effects of Bispecific Antibodies

General Safety Profile

Cytokine Release Syndrome (1/4)

Neurotoxicity and ICANS (1/2)

Infection Risk (1/3)

Low Blood Cell Counts

T-cell Exhaustion

Teclistamab Side Effect Profile

Elranatamab Side Effect Profile

Talquetamab Side Effect Profile

Linvoseltamab Side Effect Profile

Side Effect Management and Support

CRS Prevention

ICANS Prevention

Infection Prevention (1/4)

Keep Your Healthcare Team Informed

Quality of Life Impact

FDA Approved Bispecific Antibodies

Teclistamab (TECVAYLI)

Elranatamab (ELREXFIO)

Talquetamab (TALVEY)

Linvoseltamab (LYNOZYFIC)

Bispecific Antibodies in Clinical Trials

Bispecific Antibody Targets

ABBV-383 (Abbvie)

Cevostamab (Genentech)

Treatment Strategies with Bispecific Antibodies

Bispecific Combinations (1/2)

Immunotherapy Treatment Sequencing (1/3)

Bispecifics for Newly Diagnosed Myeloma

Bispecifics in High-Risk Myeloma

Relapse on Bispecific Antibody Therapy

Refractory to Bispecific Antibody Therapy

Caregiver Role in Bispecific Antibody Therapy

Financial Resources for Bispecific Antibody Therapy

Pharmaceutical Support Resources

HealthTree Financial Resources

Future Considerations of Bispecific Antibody Therapy

Eliminating Disparities

Bispecifics in the Real World

Share Your Experience

Questions to Ask Your Doctor about Bispecific Antibody Therapy

Additional Resources

HealthTree Resources

External References